Authors: Kaneko S, Dotsu Y, Inoue T, Motokawa T, Yoshimuta T, Mori M, Morikawa T, Honda N, Akagi K, Tomono H, Matsuo M, Taniguchi H, Takemoto S, Mukae H.
DOI: 10.3389/fonc.2025.1708575
Abstract Summary
This case report describes the first documented instance of amivantamab-induced myocardial injury in a lung cancer patient. Despite tachycardia being the only symptom and normal cardiac biomarkers, imaging revealed decreased heart function. Early detection and intervention allowed continued treatment, highlighting the importance of monitoring cardiac symptoms even without elevated biomarkers.
Why Brain? đź§
First reported case of amivantamab-induced myocardial injury in lung cancer treatment, emphasizing need for cardiac monitoring even without elevated biomarkers and potential for reversible damage with early intervention.
License: CC BY.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
